How to Cite
Abstract
Giant cell tumor of bone (GCTB) is a locally aggressive and rarely metastasizing neoplasm consisting of neoplastic mononuclear stromal cells of uniform appearance with an admixture of macrophages and osteoclast-like giant cells. A small proportion of cases are malignant [1]. Drug treatment of this tumor with denosumab is becoming increasingly popular because its benefits are undeniable. For example, it reduces the likelihood of extensive surgical intervention, is associated with a rapid and clinically significant reduction in the severity of the pain syndrome, and reduces the risk of disease recurrence. However, there have recently been rare reports of clinical cases of malignant transformation of GCTB with denosumab treatment [2]. We present an extremely rare clinical case of malignant transformation of GCTB, presumably after denosumab therapy, for which histological material was reviewed at the Pathology Department of the N.N. Blokhin National Medical Research Center of Oncology.
References
WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer. 2020.
Broehm C.J., Garbrecht E.L., Wood J., Bocklage T. Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep Med. 2015; 2015: 767198.-DOI: https://doi.org/10.1155/2015/767198.
Behjati S., Tarpey P.S., Presneau N., et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45: 1479-1482.-DOI: https://doi.org/10.1038/ng.2814.
Presneau N., Baumhoer D., Behjati S., et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015; 1: 113-123.-DOI: https://doi.org/10.1002/cjp2.13.
Khazaei S., De Jay N., Deshmukh S., et al. H3.3 G34W Promotes growth and impedes differentiation of osteoblast-like mesenchymal progenitors in giant cell tumor of bone. Cancer Discov. 2020; 10(12): 1968-1987.-DOI: https://doi.org/10.1158/2159-8290.CD-20-0461.
Verma V., Puri A., Shah S., et al. Giant cell tumor developing in paget's disease of bone: a case report with review of literature. J Orthop Case Rep. 2016; 6(4): 103-107.-DOI: https://doi.org/10.13107/jocr.2250-0685.594.
Borgers A., Peters S., Sciot R., De Smet L. Giant cell tumor of distal phalanx in an adolescent with Goltz-Gorlin syndrome. Genet Couns. 2014; 25(4): 445-51.
Musharbash F.N., Edelstein A., El Abiad J.M., et al. Risk of malignant transformation of giant cell tumors of bone is 8 times lower with megavoltage vs. orthovoltage radiation therapy. Agarwal M., ed. Sarcoma. 2022; 2022: 1-7.-DOI: https://doi.org/10.1155/2022/7216296.
Mori K., Berreur M., Blanchard F., et al. Receptor activator of nuclear factor-κB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep. 2007; 1365-1371.-DOI: https://doi.org/10.3892/or.18.6.1365.
van Langevelde K., Cleven A.H.G., Navas Cañete A., et al. Malignant transformation of giant cell tumor of bone and the association with denosumab treatment: a radiology and pathology perspective. Sarcoma. 2022; 2022: 3425221.-DOI: https://doi.org/10.1155/2022/3425221.
Hartmann W., Harder D., Baumhoer D. Giant cell-rich tumors of bone. Surg Pathol Clin. 2021; 14(4): 695-706.-DOI: https://doi.org/10.1016/j.path.2021.06.010.
Tariq M.U., Umer M., Khan Z., et al. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists. Ann Diagn Pathol. 2020; 45: 151479.-DOI: https://doi.org/10.1016/j.anndiagpath.2020.151479.
Roitman P.D., Jauk F., Farfalli G.L., et al. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls. Hum Pathol. 2017; 63: 89-97.-DOI: https://doi.org/10.1016/j.humpath.2017.02.008.
Yoshida K.I., Nakano Y., Honda-Kitahara M., et al. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Mod Pathol. 2019; 32(12): 1751-1761.-DOI: https://doi.org/10.1038/s41379-019-0318-5.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024